SmithKline receives non-approvable letter for Factive

SmithKline (SBH; LSE:SB) received a non-approvable letter from the FDA for its Factive gemifloxacin broad spectrum fluoroquinolone antibiotic to treat respiratory tract infections. SBH said it is work...